Search
Amgen Taiwan
×

Do you want to link to this External Site and leave Amgen.com.tw?

No, Return to Amgen.com.tw  Yes, Leave Amgen.com.tw

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

Do you want to link to this Amgen website outside of Taiwan and leave Amgen.com.tw?

No, Return to Amgen.com.tw  Yes, Leave Amgen.com.tw

YOU ARE NOW LEAVING THIS WEBSITE. Amgen Taiwan Limited takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

Products

At Amgen, our mission is to serve patients. As a science-based, patient-focused organisation, we discover and develop innovative therapies to treat serious illnesses. Our medicines have made a dramatic difference in the lives of millions.

BLINCYTO® (blinatumomab)

Product License No. 001040

1.1 MRD-positive B-cell Precursor ALL
BLINCYTO is indicated for the treatment of B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%.

1.2 Relapsed or Refractory B-cell Precursor ALL
BLINCYTO is indicated for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).

BLINCYTO® Approved Package Insert

BLINCYTO® Medication Guide

Kyprolis® (carfilzomib)

Product License No. 027068

1.1 Combination Therapy
Kyprolis is indicated in combination with dexamethasone or with lenalidomide plus dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy.

Kyprolis® Approved Package Insert

Kyprolis® (carfilzomib) for injection 30mg

Product License No. 027490

1.1 1.1 Combination Therapy
Kyprolis is indicated in combination with dexamethasone or with lenalidomide plus dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy.

Kyprolis® Approved Package Insert

Prolia® (denosumab)

Product License No. 000918

Treatment of postmenopausal women with osteoporosis at high risk for fracture.

Explanation: For postmenopausal women with osteoporosis in any one of the following situations:

  • those patients with a history of osteoporotic fracture, or multiple risk factors for fracture;
  • or those who have failed or are intolerant to other available osteoporosis therapies.
In postmenopausal women with osteoporosis, Prolia® reduces the incidence of vertebral, non-vertebral, and hip fractures.

Treatment to increase bone mass in men with osteoporosis at high risk for fracture.

Explanation: Prolia® is indicated for treatment to increase bone mass in men with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy.

Treatment of bone loss in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer.

Explanation: Prolia® also reduced the incidence of vertebral fractures for these patients.

Prolia® Approved Package Insert

Prolia® Medication Guide

"Amgen" Repatha® (evolocumab)

Orphan Drug Product License No. 000018

Homozygous familial hypercholesterolaemia: Repatha is indicated as an adjunct treatment to diet and other lipid-lowering therapy (e.g., statins, ezetimibe, LDL apheresis) to reduce LDL-C. However, patients with LDLR-negative mutations are exempt. 

Limitations of Use: The effect of Repatha on cardiovascular morbidity and mortality has not yet been determined.

"Amgen" Repatha® Approved Package Insert

Repatha® (evolocumab)

Product License No. 001033

1.1   Prevention of Cardiovascular Events

In adults with established cardiovascular disease, REPATHA is indicated to reduce the risk of myocardial infarction, stroke, and coronary revascularization.

1.2   Primary Hyperlipidemia (Including Heterozygous Familial Hypercholesterolemia)

REPATHA is indicated as an adjunct to diet, alone or in combination with other lipid-lowering therapies (e.g., statins, ezetimibe), for the treatment of adults with primary hyperlipidemia to reduce low-density lipoprotein cholesterol (LDL-C).


Repatha® Approved Package Insert

Vectibix® (panitumumab)

Product License No. 000941

Vectibix® is indicated for the treatment of adult patients with wild-type RAS metastatic colorectal cancer (mCRC):

  • in first-line in combination with FOLFOX or FOLFIRI.
  • as monotherapy after failure of fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.

Vectibix® Approved Package Insert

XGEVA® (denosumab)

Product License No. 000924

1.1 Multiple Myeloma and Bone Metastasis from Solid Tumors

XGEVA® is indicated for the prevention of skeletal-related events in patients with multiple myeloma and in adult patients with bone metastases from solid tumors.

Limitation of Use: XGEVA® is not indicated for the prevention of skeletal-related events in patients with multiple myeloma.

1.2 Giant Cell Tumor of Bone

XGEVA® is indicated for the treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity [see Clinical Trials (14.2)].

1.3 Hypercalcemia of Malignancy

XGEVA® is indicated for the treatment of hypercalcemia of malignancy refractory to bisphosphonate therapy.

XGEVA® Approved Package Insert

XGEVA® Medication Guide

Contact Us

Amgen Taiwan

For media inquiries, please contact us at JHung01@amgen.com.

For medical inquiries, please contact the Amgen Taiwan medical team by telephone: 00801611483, and by email: medinfo.JAPAC@amgen.com.